Companies: 10,795·Total market cap: $144.5T
BioVie Inc.

BioVie Inc.

BIVINASDAQHealthcare● Active
$1.69
+$0.09(+5.63%)
Market Cap$12745708
P/E Ratio—
52W High$12.1
52W Low$1.06
Overview
Stock ranking:Biotechnology·Healthcare·View All Market Cap Rankings →

BioVie Inc. (BIVI) Stock Overview

Key statistics and deep links to earnings, valuation, revenue, dividends, and more.

FMP · BIVI · as of Jun 8, 2026

Key Statistics

EPS (TTM)$-1.47bivi eps ttm · bivi earnings per shareEarnings history
PE Ratio (TTM)—bivi pe ratio ttm · bivi price to earningsPE Ratio deep dive
Revenue (TTM)0.00bivi revenue ttm · bivi annual revenueFull revenue history
Dividend YieldNo Dividenddoes bivi pay dividends · bivi dividend yieldDividend history
Shares Outstanding1.5Mbivi shares outstanding · bivi floatShares outstanding history
Next EarningsSep 2, 2026Est.bivi earnings date · bivi next earningsEarnings history

Explore BioVie Inc. Data

bivi stock data · financials
Market Cap$12.7Mbivi market cap · bivi valuation
Analyst Forecast$— · Buy
DividendsNo Dividenddoes biovie inc. pay dividends · bivi dividend yield
Revenue—biovie inc. annual revenue · bivi revenue
EarningsEPS $-12.12+83.41%bivi earnings · bivi eps
PE Ratio—bivi pe ratio · bivi price to earnings

Financial Snapshot

Full Financials
FY 2025Revenue$0.00
202320242025
biovie inc. revenue · bivi revenue 2025
FY 2025Net Income-$17.5M▲ +45.39% YoY
202320242025
biovie inc. net income · bivi profit 2025
FY 2025EPS$-12.12▲ +83.41% YoY
202320242025
bivi eps · biovie inc. earnings per share 2025
TTM:Revenue: $0.00Net Income: -$19.9MEPS: $-1.47View income statement →

Analyst Ratings & Price Target

Full Forecast
SellBuy
Buy5 analystsis bivi a buy · bivi analyst rating
Strong Buy
0
Buy
5
Hold
0
Sell
0
Strong Sell
0
12-Month Price Target
$—Low
$1.69Current
$—Avg Target
$—High
bivi price target · bivi 12 month forecast

Total: 5 · Buy rate: 100.0%

Stock Performance

Full History
1D+5.63%
1W+3.68%
1M+14.97%
3M+24.26%
YTD+45.69%
1Y-84.91%
5Y-99.89%

About BioVie Inc.

CEOCuong Viet Do
IPO DateSep 18, 2020
Employees14
CountryUS
Websitebioviepharma.com

BioVie Inc. a clinical stage biotechnology company, engages in the discovery, development, and commercialization of drugs therapies in the United States. Its products in pipeline include BIV201, whic…

BiotechnologyHealthcareNASDAQUS

what is biovie inc. · bivi stock overview · biovie inc. company profile · who is biovie inc. ceo · bivi NASDAQ · biovie inc. headquarters · biovie inc. business segments

About Stock Overview & Key Data

BioVie Inc. (BIVI) is a Healthcare company in the Biotechnology industry, listed on NASDAQ since Sep 18, 2020. As of the latest trading session, BIVI stock price is $1.69, with a market capitalization of $12.7M. The stock has returned -84.91% over the past 12 months and +45.69% year-to-date.

According to 5 Wall Street analysts, the consensus rating for BioVie Inc. stock is Buy, with an average 12-month price target of $—. In fiscal year 2025, BioVie Inc. reported revenue of — and net income of -$17.5M. For detailed data — including BioVie Inc. revenue history, earnings, dividends, and PE ratio — use the tabs above.

Frequently Asked Questions

As of the latest trading session, BioVie Inc. (BIVI) stock price is $1.69. The stock is traded on NASDAQ under the ticker symbol BIVI. The 52-week range is $1.06 – $12.10.

BIVI stock priceBIVI quote todaylive ticker
Data provided by Financial Modeling PrepLast updated: Jun 8, 2026Not investment advice